We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Pharmaceutical Certification for Cell Therapy Obtained by Bio Elpida

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pharmaceutical Certification for Cell Therapy Obtained by Bio Elpida"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Bio Elpida (www.bio-elpida.com) is a new biotech company based in Lyon – France, world-wide center of excellence for the pharmaceutical and biotechnology industry. Already expert in innovative therapy development, Bio Elpida has reached the next level in receiving from AFSSAPS (the French regulatory bodies) the pharmaceutical site accreditation. The company is now able to produce clinical trial material for stem cell, regenerative, autologous, anticancer therapies
Bio Elpida, young CMO dedicated to innovative therapies

In parallel to the Cell therapy booming, regulatory bodies are more or more stringent and are now requiring  GMP certification for any clinical material for cell therapy.

Bio Elpida has been founded in 2009 by 2 entrepreneurs (Benoît Pinteur - PDG - and Gilles Devillers) but also around a team of hyper-specialists in the field of innovative therapies. Thanks to the complementary and solid experience of its staff, Bio Elpida offers services from pharmaceutical development to clinical batch manufacturing and regulatory dossier. Bio Elpida is also mastering the logistic for autologous medication (one unique drug specifically made for one identified patient) and other complex immune therapies.